07.03.2011 Meetings with Swissmedic 4th SwAPP Experts Exchange Expertise Meetings Thursday, March 3, 2011 Dr. Urs Kopp, Swissmedic Swissmedic • Swiss Agency for Therapeutic Products • Hallerstrasse 7 • CH-3000 Bern • www.swissmedic.ch How to find the documents… www.swissmedic.ch Swissmedic Documents: Performance Human medicines Legal basis (and Forms and Checklists) 2 4th ExEx SwAPP Meeting 2011 / 3.3.2011 1 07.03.2011 Administrative ordinances found: Scientific Advice Pre-Submission Clarification 3 But some forms as well: Forms and Checklists Forms the same for all 3 meeting types 4 4th ExEx SwAPP Meeting 2011 / 3.3.2011 2 07.03.2011 Process (shared between 3 versions) Apply for meeting: turn in form to Case Management Define Meeting type Define Questions fivefold and electronic Check the number of questions to be reasonable for an (max.) 1.5 hour meeting Propose some dates for meeting (next 4- 8 weeks) Decision sent to applicant (if denied Swissmedic includes reasons) Internal team meeting – decide on date and preparatory work Meeting at Swissmedic (or Phone / Video) (cf guidelines) Minutes proposed by applicant and revised / rectified by Swissmedic Invoice SM (200 CHF / working hour / per involved Swissmedic expert) 5 Aim Similar to EMA guidelines and system Easy to understand 3 guidelines Larger parts of these 3 guidelines are similar Make a more systematic approach To encourage us to meet industry 6 4th ExEx SwAPP Meeting 2011 / 3.3.2011 3 07.03.2011 interests Backstage: •Finances? •Willingness? Civil Coordinationservant as meetings mechanisms advisor science policy Frontstage: •Presentation? knowledge CONFLICTS 7 Only one of many sources for advice! The Media The Internet Personal study Personal Contacts Patient organizations Universities Lobbyists Politicians Offices Foreign Consultants Foreign Governments International Bodies such as WHO, ICH, …. WHO close to declaring swine flu a pandemic by Rich Bowden - Jun 11 2009, 03:40 Img: WHO headquarters, Geneva. Credit: Yann Forget 8 4th ExEx SwAPP Meeting 2011 / 3.3.2011 4 07.03.2011 Scientific Advice 22nd Annual EuroMeeting Plenary, 8 March 2010, Monaco: „The process to develop new medicines and bring them to patients is neither efficient nor effective“: ⇒ make better use of scientific advice and meetings between regulators and industry (E. Abadie, Head CHMP) Before final development or evaluation (e.g. clinical study design, PV-plan CH, …) The definition of the problem will be the focal point of all your problem-solving efforts! Gather facts Reverse the Problem / “Front” Advice = Not a decision! 9 Advantages: Fewer failure due to insufficient adherence to regulatory principles in the clinical development Clinical endpoint indications Insufficient or irrelevant clinical effect or unfavorable safety Extrapolation (or not!) to other patient groups Biotech: quality / manufacturing variations (CMC) Will not prevent you from a negative decision but reduces the risk 10 4th ExEx SwAPP Meeting 2011 / 3.3.2011 5 07.03.2011 Hints for the meeting: DO‘s You are the owner of the data – take all of them into account and discuss based on them Focus on science and regulatory principles Listen to and understand the position of the agency Open to compromise (even after the meeting) Ensure that the scientific advice is well understood Limited number of attendees that have the necessary background DON’T’s Expectation that you are the only owner of the data and nobody else understands Scientific reference to the position of the EMA / FDA /…tell us!!, tell us differences, but no general reference (“but XY.. has approved”) Argumentation without taking the point of the agency Use of internal abbreviations Using Marketing arguments instead of scientific view for the drug Ask for approval 11 Competition…. is welcome! outcome likely to be different enhances chances of success tell us differences (advice / guidelines) – ask for opinion accept limited capacity of Swissmedic 12 4th ExEx SwAPP Meeting 2011 / 3.3.2011 6 07.03.2011 Pre-Submission Meeting 6 – 12 months before submission of the application Questions as: How to prepare documentation What legal basis is applicable for the product §13 LTP ….. NOT is the product approvable (we tell after assessment) NOT how do I need to apply in CH for XY (go to a consultant) Cf for eCTD: Trial submission can be done Written answer if more effective Attendees: regulatory experts 13 Clarification Meeting After List of Question received by applicant Questions in writing on: How to understand SM questions (rephrasing / restating observation) Patient groups / Clinical use Strategy for responses to SM questions Rough time estimate depending on strategy / additional data NOT final labeling decision NOT final decision and failure risks Attendees: Scientists / Clinicians 14 4th ExEx SwAPP Meeting 2011 / 3.3.2011 7 07.03.2011 Swissmedic experience Roughly 40 meetings in 2009 SM in general happy with the meetings Workload as an issue As the number of fulltime-experts at Swissmedic is limited we sometimes get support by our expert committee 15 Annual Report 16 4th ExEx SwAPP Meeting 2011 / 3.3.2011 8 07.03.2011 Your chance! 17 4th ExEx SwAPP Meeting 2011 / 3.3.2011 9
© Copyright 2024